ArticleESMO gastrointestinal oncology2025
17.6% of patients in a German cohort with exocrine pancreatic cancer were diagnosed with a genetic tumor syndrome-a case for universal genetic testing?
Abstract read
In one paragraph
Article in ESMO gastrointestinal oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
56 authors.
D WilliamInstitute for Clinical Genetics, University Hospital Carl Gustav Carus at TUD Dresden University of Technology and Faculty of Medicine of TUD Dresden University of Technology, Dresden.
M BermúdezInstitute for Clinical Genetics, University Hospital Carl Gustav Carus at TUD Dresden University of Technology and Faculty of Medicine of TUD Dresden University of Technology, Dresden.
A KüblerInstitute for Clinical Genetics, University Hospital Carl Gustav Carus at TUD Dresden University of Technology and Faculty of Medicine of TUD Dresden University of Technology, Dresden.
C KahlertDepartment for Visceral, Thoracic and Vascular Surgery, University Hospital Carl Gustav Carus at TUD Dresden University of Technology and Faculty of Medicine of TUD Dresden University of Technology Dresden, Dresden.
M DistlerDepartment for Visceral, Thoracic and Vascular Surgery, University Hospital Carl Gustav Carus at TUD Dresden University of Technology and Faculty of Medicine of TUD Dresden University of Technology Dresden, Dresden.
J WeitzDepartment for Visceral, Thoracic and Vascular Surgery, University Hospital Carl Gustav Carus at TUD Dresden University of Technology and Faculty of Medicine of TUD Dresden University of Technology Dresden, Dresden.
S UhrigComputational Oncology Group (CO), Molecular Precision Oncology Program (MPOP), German Cancer Research Center (DKFZ), Heidelberg.
M FröhlichComputational Oncology Group (CO), Molecular Precision Oncology Program (MPOP), German Cancer Research Center (DKFZ), Heidelberg.
B HutterComputational Oncology Group (CO), Molecular Precision Oncology Program (MPOP), German Cancer Research Center (DKFZ), Heidelberg.
D AustInstitute of Pathology, University Hospital Carl Gustav Carus at TUD Dresden University of Technology and Faculty of Medicine of TUD Dresden University of Technology, Dresden.
G BarettonInstitute of Pathology, University Hospital Carl Gustav Carus at TUD Dresden University of Technology and Faculty of Medicine of TUD Dresden University of Technology, Dresden.
P WimbergerDepartment of Gynecology and Obstetrics, University Hospital Carl Gustav Carus at TUD Dresden University of Technology and Faculty of Medicine of TUD Dresden University of Technology, Dresden.
K KastDepartment of Gynecology and Obstetrics, University Hospital Carl Gustav Carus at TUD Dresden University of Technology and Faculty of Medicine of TUD Dresden University of Technology, Dresden.
C MeiselDepartment of Gynecology and Obstetrics, University Hospital Carl Gustav Carus at TUD Dresden University of Technology and Faculty of Medicine of TUD Dresden University of Technology, Dresden.
L GieldonInstitute for Clinical Genetics, University Hospital Carl Gustav Carus at TUD Dresden University of Technology and Faculty of Medicine of TUD Dresden University of Technology, Dresden.
J PorrmannInstitute for Clinical Genetics, University Hospital Carl Gustav Carus at TUD Dresden University of Technology and Faculty of Medicine of TUD Dresden University of Technology, Dresden.
J WagnerInstitute for Clinical Genetics, University Hospital Carl Gustav Carus at TUD Dresden University of Technology and Faculty of Medicine of TUD Dresden University of Technology, Dresden.
M ArltInstitute for Clinical Genetics, University Hospital Carl Gustav Carus at TUD Dresden University of Technology and Faculty of Medicine of TUD Dresden University of Technology, Dresden.
M FrankeInstitute for Clinical Genetics, University Hospital Carl Gustav Carus at TUD Dresden University of Technology and Faculty of Medicine of TUD Dresden University of Technology, Dresden.
J FischerInstitute for Clinical Genetics, University Hospital Carl Gustav Carus at TUD Dresden University of Technology and Faculty of Medicine of TUD Dresden University of Technology, Dresden.
K HackmannInstitute for Clinical Genetics, University Hospital Carl Gustav Carus at TUD Dresden University of Technology and Faculty of Medicine of TUD Dresden University of Technology, Dresden.
S KreutzfeldtNational Center for Tumor Diseases (NCT), NCT Heidelberg, a partnership between DKFZ and Heidelberg University Hospital, Heidelberg.
A MockNational Center for Tumor Diseases (NCT), NCT Heidelberg, a partnership between DKFZ and Heidelberg University Hospital, Heidelberg.
C E HeiligNational Center for Tumor Diseases (NCT), NCT Heidelberg, a partnership between DKFZ and Heidelberg University Hospital, Heidelberg.
D B LipkaNational Center for Tumor Diseases (NCT), NCT Heidelberg, a partnership between DKFZ and Heidelberg University Hospital, Heidelberg.
M-V TeleanuNational Center for Tumor Diseases (NCT), NCT Heidelberg, a partnership between DKFZ and Heidelberg University Hospital, Heidelberg.
R F SchlenkNational Center for Tumor Diseases (NCT), NCT Heidelberg, a partnership between DKFZ and Heidelberg University Hospital, Heidelberg.
B BrorsComputational Oncology Group, Molecular Precision Oncology Program, NCT Heidelberg and DKFZ, Heidelberg.
D HübschmannComputational Oncology Group (CO), Molecular Precision Oncology Program (MPOP), German Cancer Research Center (DKFZ), Heidelberg.
N ParamasivamComputational Oncology Group (CO), Molecular Precision Oncology Program (MPOP), German Cancer Research Center (DKFZ), Heidelberg.
D RichterDepartment of Translational Medical Oncology, National Center for Tumor Diseases (NCT), NCT Dresden, a partnership between DKFZ, Faculty of Medicine and University Hospital Carl Gustav Carus, TUD Dresden University of Technology, and Helmholtz-Zentrum Dresden-Rossendorf (HZDR), Dresden.
K BeckDepartment of Internal Medicine V, Heidelberg University Hospital, Heidelberg.
K PfützeSample Processing Laboratory, German Cancer Research Center (DKFZ) and National Center for Tumor Diseases (NCT) Heidelberg, Heidelberg.
I BuchhalterOmics IT and Data Management Core Facility, German Cancer Research Center (DKFZ) and German Cancer Consortium (DKTK), Heidelberg.
W WeichertSchool of Medicine, Institute of Pathology, Technical University of Munich, Munich.
T HeroldDepartment of Medicine III, University Hospital, Ludwig Maximilians University Munich, Munich.
K SpiekermannDepartment of Medicine III, University Hospital, Ludwig Maximilians University Munich, Munich.
P J JostDivision of Oncology, Department of Internal Medicine, Medical University of Graz, Graz, Austria.
U KeilholzCharité Comprehensive Cancer Center, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin.
F KlauschenInstitute of Pathology, Ludwig Maximilian University of Munich, Munich.
S BauerDepartment of Medical Oncology and Sarcoma Center, West German Cancer Center, University Duisburg-Essen, Medical School, Essen.
J T SivekeDKTK, Partner Site Essen, German Cancer Consortium (DKTK), Heidelberg.
T KindlerUniversity Cancer Center and Department of Internal Medicine III, University Medical Center Mainz, Mainz.
M BoerriesInstitute of Medical Bioinformatics and Systems Medicine, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg.
A L IllertDepartment of Internal Medicine I, Division of Hematology, Oncology and Stem Cell Transplantation, University Medical Center Freiburg, Freiburg im Breisgau.
M BitzerDepartment of Internal Medicine I, University Hospital Tübingen, Eberhard Karls University of Tübingen, Tübingen.
K Schulze-OsthoffDepartment of Molecular Medicine, Interfaculty Institute for Biochemistry, Eberhard Karls University of Tübingen, Tübingen.
P SchirmacherInstitute of Pathology, Heidelberg University Hospital, Heidelberg.
A StenzingerInstitute of Pathology, Heidelberg University Hospital, Heidelberg.
P HorakNational Center for Tumor Diseases (NCT), NCT Heidelberg, a partnership between DKFZ and Heidelberg University Hospital, Heidelberg.
C HeiningDepartment of Translational Medical Oncology, National Center for Tumor Diseases (NCT), NCT Dresden, a partnership between DKFZ, Faculty of Medicine and University Hospital Carl Gustav Carus, TUD Dresden University of Technology, and Helmholtz-Zentrum Dresden-Rossendorf (HZDR), Dresden.
G FolprechtDepartment of Medicine I, University Hospital Carl Gustav Carus at TUD Dresden University of Technology and Faculty of Medicine of TUD Dresden University of Technology, Dresden, Germany.
S FröhlingNational Center for Tumor Diseases (NCT), NCT Heidelberg, a partnership between DKFZ and Heidelberg University Hospital, Heidelberg.
H GlimmDepartment of Translational Medical Oncology, National Center for Tumor Diseases (NCT), NCT Dresden, a partnership between DKFZ, Faculty of Medicine and University Hospital Carl Gustav Carus, TUD Dresden University of Technology, and Helmholtz-Zentrum Dresden-Rossendorf (HZDR), Dresden.
E SchröckInstitute for Clinical Genetics, University Hospital Carl Gustav Carus at TUD Dresden University of Technology and Faculty of Medicine of TUD Dresden University of Technology, Dresden.
A JahnInstitute for Clinical Genetics, University Hospital Carl Gustav Carus at TUD Dresden University of Technology and Faculty of Medicine of TUD Dresden University of Technology, Dresden.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Yields for (likely) pathogenic germline variants (PGVs) in cancer predisposition genes (CPGs) in pancreatic cancer (PCA) cases range from 5% to 10% in initial literature to 15% to 20% in recent literature. PGVs can impact therapy recommendations and cancer surveillance for individuals and families. Patients and methods: We retrospectively evaluated prospective cancer predisposition testing in 125 patients with exocrine PCA from a single-center clinical genetics clinic ( Results: PGVs were identified in 21.6% of patients ( Conclusions: These findings support ASCO and NCCN recommendations for germline testing in all PCA patients. We suggest offering large-panel genetic diagnostics early in clinical management, regardless of clinical parameters, with ongoing evaluation and adjustment of the gene panel.
Indexed as
familial pancreatic cancergenetic tumor syndromesgermline testinghereditary cancerpancreatic adenocarcinomaparallel germline and tumor testingtargeted therapy
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.